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Summary:  
 
Mitochondrially-bound hexokinase II (mtHKII) has long been known to confer cancer cells 
with their resilience against cell death. More recently, mtHKII has emerged as a powerful 
protector against cardiac cell death. mtHKII protects against IR injury in skeletal muscle and 
heart, attenuates cardiac hypertrophy and remodelling, and is one of the major end-effectors 
through which ischemic preconditioning protects against myocardial ischemia-reperfusion 
injury. Mechanisms of mtHKII cardioprotection against reperfusion injury entail the 
maintenance of regulated OMM permeability during ischemia and reperfusion resulting in 
stabilisation of mitochondrial membrane potential, the prevention of OMM breakage and 
cytochrome C release, and reduced ROS production. Increasing mtHK may also have 
important metabolic consequences, such as improvement of glucose-induced insulin release, 
prevention of acidosis through enhanced coupling of glycolysis and glucose oxidation, and 
inhibition of fatty acid oxidation. Deficiencies in expression and distorted cellular signalling 
of HKII may contribute to the altered sensitivity of diabetes to cardiac ischemic diseases. 
The interaction of HKII with the mitochondrion constitutes a powerful endogenous molecular 
mechanism to protect against cell death in almost all cell types examined (neurons, tumours, 
kidney, lung, skeletal muscle, heart). The challenge is now to harness mtHKII in the treatment 
of infarction, stroke, elective surgery and transplantation. Remote ischemic preconditioning, 
metformin administration and miR-155/miR-144 manipulations are potential means of doing 
just that. 
 
 
Key words: ischemia-reperfusion injury; mPTP; cell death; diabetes; glycolysis, 
mitochondria 
 
Abbrevations: AMPKamp-activated protein kinase; ANTadenine nucleotide transporter; 
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INTRODUCTION 
 
The two leading causes of human mortality are cancer and cardiovascular disease. Curiously, 
the directed goal of therapy against these diseases is diametrically opposed: in cancer we 
strive to kill the tumour cells, whereas in heart disease we strive to protect cardiac cells from 
being killed. The question arose whether the processes that promote cell survival in cancer 
cells could potentially be used in promoting survival in the heart, and whether our 
understanding of the death processes in the heart could be harnessed in the treatment of 
cancer. The cancer literature has suggested that the resilience of cancer cells against cell death 
is, at least partly, due to highly elevated levels of HKII bound to mitochondria (Pedersen, 
2007).  Knowing that mitochondrial dysfunction has emerged as a major mediator of cell 
death in ischemia-reperfusion injury of the heart, we considered the possibility that HKII is 
one of the critical regulators of mitochondrial dysfunction in cardiac IR injury. This 
consideration was primarily based on the pioneering work by others demonstrating the pivotal 
role of HK in mitochondrial function and cell death in non-cardiovascular research fields. 
Instrumental in these HK pioneering studies were the discoveries of HK binding to and 
regulation of mitochondrial VDAC (Fiek et al., 1982; Brdiczka, 1990; Forte et al., 1987; 
Rostovtseva et al., 2005; Rostovtseva et al., 2008A), and the regulatory role of HK in 
mitochondrial pore formation (Nakshima et al., 1986; Marzo et al., 1998).    
Various work by us and others have now clearly demonstrated that mitochondrially-bound 
HKII is indeed a major determinant of infarct size and may constitute one of the end-effectors 
of ischemic preconditioning. Mitochondrial hexokinase II (and I) affects mitochondrial 
membrane potential and ROS production, regulates mPTP, and may also determine the 
direction of cardiac metabolic flux. This review summarizes current knowledge about the role 
of mitochondrially-bound hexokinase in cardioprotection and cardiac ischemia-reperfusion 
injury, adding mtHKII as a new target that may prove useful in the quest to reduce mortality 
due to cardiovascular disease. 
 
 
The Hexokinase Family 
 
The first step in the metabolism of glucose is its phosphorylation upon entrance into the cell. 
Sufficient and rapid phosphorylation is important to maintain the steep gradient of glucose 
concentration over the plasma membrane to drive continuous glucose uptake through the 
GLUT transporters, as well as to render glucose polar, and therefore incapable of exiting the 
cell. Glucose phosphorylation is catalyzed by the enzyme hexokinase, of which four isozymes 
are present within mammalian tissue. HKI, II and III are isozymes of 100 kDa, displaying 
high affinity for glucose (Km ≤ 0.3 mM) and product inhibition for G6P (Ki ≤ 0.1 mM), 
whereas HKIV (glucokinase) is 50 kDa in size, has low affinity for glucose (half-saturation at 
about 8 mM glucose) and does not show product inhibition at physiological levels of G6P 
(Wilson, 2003). Importantly, HKI and II contain a hydrophobic amino terminal mitochondrial 
binding motif, which is not present in the HKIII and IV isoforms.  
HKI is ubiquitously expressed in almost all mammalian tissues, is largely unresponsive to 
hormonal and prevailing metabolic conditions, and can be considered more of a house 
keeping protein. Surprisingly, despite being a glycolytic enzyme, and with glycolysis mainly 
being thought of as a cytosolic process, HKI is predominantly associated with mitochondria 
(Crane et al., 1953; Johnson, 1960, Abraham et al., 1964). It is suggested (Wilson, 1995, John 
et al., 2011) that HKI principally performs a catabolic function, channelling glucose into 
glycolysis for ATP production. In contrast, HKII is more variably located in either the cytosol 
or at the mitochondrial outer membrane, and is mostly expressed in insulin-sensitive tissue A
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such as heart, skeletal muscle and adipose tissue. When situated in the cytosol it directs 
glucose into glycogen synthesis, while when bound to mitochondria it primarily directs 
glucose into glycolysis (John et al., 2011). HKII expression levels and localization are highly 
regulated by (patho) physiology, hormones and metabolic state (Wilson, 2003; Heikkinen et 
al., 2000). In contrast to the abundance of HKI and HKII, HKIII shows low expression in 
most mammalian tissues, being most highly represented in lung, liver and spleen (Heumann et 
al., 1974; Furuta et al., 1996). Finally, HKIV is traditionally regarded as a glucose-sensing 
enzyme (although other HK isoforms also display glucose-sensing properties), associated with 
regualting insulin-release by pancreatic β-cell. This glucokinase is mainly expressed in liver 
and the pancreas, but can also be found in certain parts of the brain and gut (Postic et al., 
2001).  
 
 
Mitochondrial Hexokinase in Cancer 
 
As early as 1924, the pioneering work of the Nobel prize winner Otto Warburg (Warburg, 
1924) associated malignant, aggressive tumour growth with increased rates of aerobic 
glycolysis and increased lactate production, a signature now known as the Warburg effect 
(Pedersen, 2007). It took another fifty years to demonstrate mitochondrial HKII as a key 
molecular governor of this increased glycolysis (Bustamante et al., 1977; Bustamante et al., 
1981), with the expression of HKII (sometimes HKI) being increased often more than 100-
fold. Activation of the PI3K/Akt pathway, one of the most frequently mutated pathways in 
cancer (Shaw et al., 2006), and activation of PKA and PKC pathways, also commonly seen in 
cancers, may explain this increased HKII expression. DNA demethylation and HKII gene 
amplification has also been suggested to play a role (Mathulpa et al., 2009), as has the 
increased expression of hypoxia-inducible factor HIF1 (Keith et al., 2012; Semenza et al., 
2003). Although Warburg originally hypothesized that the increased reliance of tumours on 
glycolysis was due to impairments in mitochondrial function, it is now known that this is not 
the case. Mitochondria from tumours can still have normal oxidative phosphorylation with 
intact ATP synthetic capacity; however, they are often reprogrammed towards biosynthetic 
pathways supporting tumour proliferation, such that glucose and glutamine become important 
substrates feeding rewired anabolic pathways (Ward et al., 2012). Thus, the increased HKII 
expression and its binding to mitochondria not only facilitates increased aerobic glycolysis 
and lactate production (John et al., 2011), but also the channelling of glycolytic substrates into 
biosynthetic pathways for which mitochondria play a crucial role. The increase in the 
proportion of HKII that is bound to mitochondria also provides the cancer cell with resilience 
to cell death. The exact mechanism of this protection has not yet been elucidated, but it is 
known that glucose is necessary in order for mtHKII to inhibit apoptosis, indicating that this 
is an active process requiring glucose phosphorylation (Gottlob et al., 2001). Targeting the 
binding between HKII and mitochondria is currently actively pursued as a possible treatment 
against aggressive proliferative tumours. Such targeting may be achieved with 3-
bromopyruvate (Mathupala et al., 2009), methyl jasmonate (Goldin et al., 2008), 
dichloroacetate (Michelakis et al., 2010), the antifungal compounds clotrimazole and 
bifanazole (Penzo et al., 1998), and some traditional Chinese medicinal plants (Wei et al., 
2013). However, such treatment comes with a price. Our recent data (Smeele et al., 2011A) 
showing the high sensitivity of heart towards disruption of mtHKII binding and the immediate 
development of cardiac cell death, is a direct warning against any such treatment being a 
global, whole-body treatment. A nice example of this phenomenon is the use of 
anthracyclines in cancer chemotherapy, which, while very effective in cancer treatment have 
to be very carefully titrated because of their severe cardiotoxicity. It has been suggested that A
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this cardiotoxicity may be mediated in part by mito-HK dissociation via inhibition of Akt 
signalling (Pastorino et al., 2005). Thus it is of paramount importance that these drugs target 
the cancer cell through localized delivery to the tumour (Ko et al., 2012) or using compounds 
that are only taken up by the cancer cell through selective cancer-expressed transporters 
(Birsoy et al., 2013).  
 
 
Mitochondrial hexokinase and protection in non-cardiac tissues 
 
Although the primary focus of this review is on the heart, mitochondrial hexokinase has been 
shown to protect against stressors in several other organs and tissues. We demonstrated that 
decreased (mitochondrial) HKII increased IR injury in skeletal muscle (Smeele et al., 2010; 
Smeele et al, 2012). In fact, skeletal muscle IR injury was very sensitive to reductions in HKII 
(50% HKII reduction increased IR-induced cell necrosis from 36% to 76%; Smeele et al., 
2012), probably because HKII is the major HK isoform in skeletal muscle. Bryson et al. 
(2002) and Gall et al. (2011) showed that increased HK activity protects kidney epithelial 
cells against oxidant injury, whereas Ahmad et al. (2002) demonstrated that HKII protected 
human lung epithelial cells against hyperoxia and oxidative stress. Finally, mtHKII protects 
against neurodegeneration in models of Parkinson’s disease (Gimenez-Cassina et al., 2009; 
Corona et al., 2010). Therefore, it seems that the interaction of HK with mitochondria 
constitute an endogenous cellular protective mechanism against cell death that is operative in 
many tissues and organs.  
 
 
Mitochondrial Hexokinase and Metabolism 
 
Early observations (Bessman et al., 1980; Wilson, 1995), later supported by various other 
researchers, demonstrated that mitochondrially bound hexokinase preferentially uses 
mitochondrially produced ATP (in contrast to cytosolic ATP), with direct channelling of the 
produced ADP back into the mitochondria. Thus one major metabolic consequence of HK 
translocation to the mitochondria is that the ATP sensitivity of glucose phosphorylation is 
shifted from a cytosolic to a mitochondrial ATP source. Surprisingly, however, it remains 
unknown what the metabolic consequences of this translocation per se are in terms of oxygen 
consumption and energy substrate selection in intact organs/tissues. The role of mtHK in cell 
death, however, is better understood. Several seminal studies have now clearly shown the 
association between mtHK disruption and cell death, induced by stimuli such as H2O2 and/or 
UV irradiation in cellular studies (Gottlob et al., 2001; Pastorino et al., 2002; Bryson et al., 
2002; Ahmad et al., 2002) or ischemia-reperfusion in intact organs and tissues (Smeele et al., 
2011A, 2012; Pasdois et al., 2013). There are indications that enhancing mtHKII may 
increase (glucose-mediated) oxidative phosphorylation and therefore overall energy 
production in permeabilised human fibres from dilated atria (Roosima et al., 2013). These 
findings are in line with older literature showing that hexokinase can display high control 
strength over respiration in isolated mitochondria (Groen et al., 1982). Interestingly, it has 
also been suggested that an increased translocation of HKI to mitochondria increases the 
glucose sensitivity of the pancreatic β-cell to release insulin (Rabuazzo et al., 1997). Whether 
mtHK may affect cardiac (and skeletal muscle) insulin sensitivity is unknown. Clearly, more 
work needs to be done to answer these important questions as to how mtHKII affects 
metabolism of the intact heart.  
Older literature indicates that mtHK not only affects glucose metabolism, but may also 
regulate cardiac fatty acid oxidation. Mitochondrial hexokinase inhibits palmitoyl-CoA A
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synthetase through competition for ATP and thereby inhibiting palmitate activation at the 
OMM in isolated mitochondria (de Jong et al., 1970). The reported decrease in mtHK 
associated with diabetes (Katzen et al., 1970) may therefore be a contributing factor to the 
often increased fatty acid metabolism in diabetic hearts.  The reciprocal relationship was 
demonstrated by Southworth et al. who showed that perfusion of isolated hearts with fatty 
acids dislodged HKI and HKII from mitochondria (Southworth et al., 2007).  Thus, mtHK 
seems to be an ideal localization hub for the well-known competition between glucose and 
fatty acid metabolism and the regulation thereof.    
 
 
Mitochondrial hexokinase in Cardiovascular Diseases (Figure 1) 
 
HKI and HKII are both present in the heart. In adult mouse heart, HKI and HKII contribute 
approximately equally to total cardiac hexokinase activity (Smeele et al., 2011B), depending 
on the age and the nutritional/pathophysiological condition of the animal. Few data are 
available for human heart, except for a recent report by Roosimaa et al. (2013) which 
indicates that in non-dilated human atrial tissue, HKI is the most abundant isoform. In mouse 
and human skeletal muscle (Smeele et al., 2011B; Mandarino et al., 1995) however, HKII 
accounts for >80% of total HK activity.   
 
IPC Protection against I/R injury through increased mtHKII:   The discovery that short, 
non-lethal periods of ischemia activate an endogenous cardiac protection program against 
long, lethal, periods of ischemia led to a highly intensified research effort to elucidate the 
cellular mechanisms. This phenomenon was called ischemic preconditioning (IPC; Murry et 
al. 1986). Subsequent research demonstrated that IPC cellular signalling converged on the 
mitochondrion, and was associated with alterations in glycolysis (Murphy et al, 2008; Murry 
et al., 1986). Work from our laboratory at that time also noticed this interaction between 
glycolysis and mitochondrial function following non-lethal periods of ischemia. We 
demonstrated that the activation of mitochondrial oxygen consumption, due to an 
instantaneously increased cardiac workload (Zuurbier et al., 1997; Van Beek et al., 1998), 
was slowed following non-lethal periods of ischemia. However, no such slowing was 
observed when glycolysis was bypassed using high concentrations of pyruvate or lactate 
(Zuurbier et al., 2002). In other words, the changes observed in mitochondrial function 
following non-lethal ischemia were precipitated through changes evoked in glycolysis. After 
having established that the alterations in glycolysis were not due to alterations in the pentose 
phosphate pathway (Zuurbier et al., 2004), translocation of HK with non-lethal periods of 
ischemia became a likely candidate (Zuurbier et al., 2009). Finally, we demonstrated that 
reversible ischemia such as IPC induced a translocation of the glycolytic enzyme HK to the 
mitochondria (Zuurbier et al., 2005; Gürel et al., 2009). This lead us to the hypothesis that 
IPC could, at least partly, be attributed to increased HKII trafficking to the mitochondria 
(Zuurbier et al., 2009). This hypothesis was confirmed by subsequent studies showing loss of 
IPC protective effects with a peptide blocking mito-HKII binding (Smeele et al., 2011A), and 
increased IR injury with partial deletion of the HKII gene in both heart and skeletal muscle 
(Smeele et al., 2010, 2012; Wu et al., 2011). This work was recently confirmed by findings in 
Halestrap's laboratory, showing a close correlation between cardiac infarct size and the extent 
of mitochondrial HKII dissociation (Pasdois et al., 2013).  
IR, post-MI, regeneration: HK expression and cellular localisation changes dramatically 
during and after periods of ischemia. During prolonged cardiac ischemia there is an increase 
in cytosolic HK activity (Correa et al., 2008), that can be explained by solubilisation of HKII 
(but not HKI) from the mitochondria (Gürel et al., 2009; Pasdois et al., 2011). The A
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mechanism of HK detachment from the mitochondria during ischemia is, at least partly, 
related to acidification and increases in G6P (Pasdois et al., 2013). The endogenous 
adaptation following ischemia in cardiac tissue is associated with increases (~ 30-70%) in 
total and mitochondrial HK (McFalls et al., 2002; Wu et al., 2011; Yeih et al., 2011; 
Miyamoto et al., 2010).  Large increases (200-300%) in HK activity were also observed in 
regenerated skeletal muscle 2 weeks after the IR insult (Smeele et al., 2012). It thus seems 
that following an ischemic episode there is increased HK expression, presumably enhancing 
biosynthetic pathways for regeneration and growth and to offer protection against recurrent 
episodes of ischemia.  
Hypertrophy and Heart failure: During pressure overload-induced cardiac hypertrophy, 
mtHKII and total HKII protein content have been shown to increase (Wu et al., 2012; Riehle 
et al., 2011). Increased HKII expression was also recently reported in dilated human atria 
(Roosima et al., 2013). Genetic reductions in HKII resulted in exaggerated cardiac 
hypertrophy in a pressure-overload model (Wu et al., 2012). These data suggest that the 
increased HKII expression in pressure-overloaded hearts is an adaptive response, possibly 
attenuating hypertrophy through diminishing oxidative stress (Wu et al., 2012). Therapeutic 
enhancement of tissue HKII during this hypertrophic stage may therefore be a potentially 
beneficial approach.  Interestingly, while mild pressure-overload results in a relatively 
compensated hypertrophy associated with increases in HKII, the same procedure in animals 
deficient for PGC-1β resulted in decreased HKII levels, decompensated hypertrophy, and 
evidence of increased oxidative stress (Riehle et al., 2011). This data suggest that PGC-1β, a 
regulator of mitochondrial biogenesis and genes encoding for mitochondrial metabolism, is 
needed to maintain cardiac function following pressure overload by possibly preserving HKII 
expression and preventing oxidative stress. Cardiac HKII has also been shown to be severely 
reduced in a pacing-induced heart failure model in pigs (Lionetti et al., 2009). While these 
data suggest that the development of heart failure is associated with decreases in HKII, further 
studies are warranted to examine whether the reduced HKII protein levels are cause or 
consequence of cardiac failure. 
Hyperglycemia and Diabetes: Hyperglycemia in the clinical condition is currently viewed as 
an important risk factor for poor clinical outcome. In addition, the presence of hypergycemia 
in the pre-diabetic state is a strong predictor of developing diabetic disease. Acute 
hyperglycemia has been shown to induce the detachment of HK from mitochondria (Da-Silva 
et al., 2004; Pasdois et al., 2013), which may underlie its pathology.  During the development 
of diabetes, there is a shift in cardiac metabolism away from glucose metabolism towards 
fatty acid metabolism. This shift is generally associated with significant decreases in cardiac 
and muscle HKII protein content without alterations in HKI protein content (Katzen et al., 
1970; Vestergaard et al., 1995). The diabetic heart displays an altered response to IR and IPC, 
with short-term diabetes frequently offering protection against IR and attenuated IPC 
potential, and long-term diabetes resulting in worsened outcome after IR and loss of IPC 
protective effects (Miki et al., 2012). It is possible that changes in cardiac HK contribute to 
such an altered response of diabetic heart to IR and IPC.  Indeed, we have demonstrated that 
the increased protection against IR and the attenuation of IPC in the short-term type I diabetic 
heart are associated with altered mitochondrial HK binding characteristics (Gurel et al., 
2013). These data suggest that the known association between diabetes mellitus and ischemic 
cardiovascular disease may partly stem from alterations at the level of cardiac HKII 
expression. More work is needed to fully explore the role of HKII in diabetic 
cardiomyopathy.    
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Mechanisms of mtHKII-induced protection against IR injury (Figure 2):  
 
There is currently no consensus concerning the exact mechanism of mtHK protection against 
IR injury. Below we restrict our discussion to those four mechanisms for which experimental 
evidence can be found. The overarching action of mtHK is its regulatory role in the 
homeostatic cross-talk between the mitochondria and the cell. This cross-talk is set by the 
degree of permeability of the OMM and the IMM to extramitochondrial metabolites. 
The permeability of the OMM is determined by VDAC, the mitochondrial binding partner of 
HK.  HK, at least partly, regulates the permeability of VDAC for many important metabolites  
such as ATP, ADP, NADH (Rostovtseva et al., 2005). The permeability barrier of the IMM to 
protons and ions is essential to ATP synthesis by mitochondria; loss of this permeability 
barrier prevents the generation of an electrochemical gradient (mitochondrial potential) that 
drives ATP synthesis through the F0F1ATPase. This loss of the IMM permeability barrier, as 
reflected by the opening of a non-specific pore in the IMM, the so-called mPTP, is currently 
considered the final event causing IR injury and irreversible cell death (Halestrap et al., 
2009). The molecular identity of the mPTP was recently suggested to consist of dimers of the 
F0F1ATPase localised on the IMM (Giorgio, 2013), with HK, VDAC, ANT and CypD as 
important regulators of the mPTP (see also Figure 2). It is through this mPTP complex that 
HK mediates its decisive role in IR injury and cardioprotection. It should be noted that there 
may also be a role for the mitochondrial phosphate carrier (PiC) as important regulator of the 
mPTP (Leung et al., 2008). The reader is directed to literature that discusses this component 
in detail (Halestrap, 2009; Leung and Halestrap, 2008). For this review we focus primarily on 
how HK may affect the  mPTP.  
 
1) Prevention of conformational change in molecular mPTP regulation complex to stabilize 
mitochondrial membrane potential. It has been shown that mitochondrial depolarization 
occurs during cardiac ischemia and may be an early sign of irreversible injury (Lyon et al., 
2010). Mitochondrial depolarization during ischemia and early reperfusion may cause direct 
mPTP opening (Bernardi, 1992), and there is evidence that mtHKII may prevent such 
depolarization. We have recently demonstrated that acute HKII detachment from 
mitochondria in the beating heart per se (without any concomitant stress signal), using 
medium-to-high dosage (≥ 2.5 M) of a HKII dislodging peptide, acutely depolarized 
mitochondria and induced cell death, an effect which could not be explained by vascular 
obstruction or ensuing ischemia in the intact organ (Smeele et al., 2011A; Nederlof et al., 
2013). In these conditions of normoxic perfusion with a pH > 7 buffer, this depolarization can 
cause immediate mPTP opening and cell death (Bernardi, 1992). Previously, Chiara et al. 
(2008) demonstrated that the sensitivity of isolated cardiomyocytes to ROS-induced mPTP 
opening was much increased with low concentrations (< 1 M) of the HKII dislodging 
peptide. They hypothesized that detachment of HKII induced a conformational change in the 
molecular complex connecting the OMM with the IMM and the mPTP (Chiara et al., 2008). 
We would suggest that the HKII dislodging peptide fully opens VDAC, either due to loss of 
HK or other VDAC-regulating proteins, such as tubulin (Sheldon et al., 2013). VDAC is the 
most abundant protein of the OMM and is responsible for the transport of ADP/ATP and 
other metabolites (e,g, NADH, Ca
2+
 ) across the OMM (Colombini, 2004; Rostovtseva et al., 
2005; 2008A). VDAC can change between an open and “closed” state, which is almost 
impermeable to ADP and ATP,   and may thereby regulate mitochondrial respiration. The 
binding of several cytosolic proteins (tubulin, tBid, Bcl-xL, HK) with VDAC, in combination 
with OMM lipid composition and trans-membrane potential, regulate VDAC conductance. It 
was recently demonstrated that dimeric tubulin, known to interact with mitochondria in vivo, 
induced voltage-sensitive closure of VDAC, reducing ADP availability and thereby A
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mitochondrial respiration (Rostovtseva et al., 2008B).   Preliminary data (Sheldon et al., 
2013) now shows that the HKII dislodging peptide disrupts HKII and tubulin binding to 
VDAC in planar lipid bilayers, resulting in unregulated permeability of VDAC that may 
ultimately results in large ADP influx, decreasing the mitochondrial membrane potential to a 
critical level of spontaneous mPTP opening.      
2) Stabilization of mitochondrial contact sites during ischemia preventing CytC release. 
mtHKII may alternatively prevent OMM rupture and/or permeabilisation by stabilization of 
mitochondrial contact sites. Hexokinase is preferentially bound to mitochondria at locations 
where the IMM comes closest to the OMM (Brdiczka et al., 2006). These contact sites 
contain large protein complexes consisting of VDAC, ANT, cytochrome C, benzodiazepine 
receptor, cyclophilin D, cardiolipin, HK and creatine kinase. In reconstituted vesicles, 
disruption of HK from these protein complexes increases their permeability, which could be 
interpreted as analogous to increased permeability of the OMM and/or mPTP (Beutner et al., 
1998). It has been suggested that during ischemia, progressive acidosis and G6P accumulation 
dislodge HK from mitochondria (Pasdois et al., 2013). Such decrease in mtHK, together with 
increased Ca
2+
, disrupts the contact sides resulting in an increased permeability of the OMM 
for cytochrome c release. Knowing that oxidized cytochrome C is an important anti-oxidant, 
the loss of cytochrome C will result in increased ROS production at early reperfusion (Pasdois 
et al., 2011, 2013), finally resulting in mPTP opening and infarction.  
3) Maintaining mitochondrial ADP to inhibit mPTP and reduce ROS.  The activity of HK at 
the mitochondrial surface rapidly returns ADP back to the inner mitochondrial compartment 
via VDAC and ANT, thereby ensuring high levels of ADP in the vicinity of F0F1 ATPase 
dimers at early reperfusion. This “ATP/ADP” shuttle has been shown to reduce the 
mitochondrial membrane potential and limit ROS production (Da-Silva et al., 2004; Santiago 
et al., 2008; Wu et al., 2012).  The reduction in ROS production offered by active mtHK can 
range from >90% (going from zero to normal mtHK levels in isolated brain mitochondria 
;Da-Silva et al., 2004), to 70% (with activation of mtHK in isolated rat heart mitochondria; 
Santiago et al, 2008) and to 20% (with 40% increase in mtHKII in neonate rat 
cardiomyocytes; Wu et al., 2012). 
4) Inhibition of ATP hydrolysis during ischemia. Maintaining HKII at the mitochondria 
during ischemia may impair cytosolic ATP entrance into the mitochondria (Perevoshchikova 
et al., 2010) during ischemia, thereby attenuating mitochondrial hydrolysis of cytosolic ATP 
(through reversed mode of mitochondrial F1F0 ATPsynthase). Prevention of a critical 
depletion of ATP by the mitochondria during ischemia can significantly reduce anaerobic 
glycolysis and lactate accumulation, cardiac contracture and cell death induced by IR 
interventions (Steenbergen et al., 1990; Jennings, 2013).  
 
Structural obstruction of pro-apoptotic protein binding to mitochondria. It has been 
proposed, in cellular studies employing oxidant agents, that mtHKII may be cytoprotective 
through structural opposition to the mitochondrial binding of pro-apoptotic proteins such as 
Bax or Bad (Pastorino et al., 2002). However, we and others have been unable to show a role 
for Bax in mtHKII-mediated protection against IR injury in isolated hearts (Smeele et al., 
2011A; Pasdois et al., 2013) or skeletal muscle (Smeele et al., 2012). The purely structural 
basis of mtHKII cytoprotection by steric hindrance is also challenged by several studies which 
demonstrate that glucose must be present in order for HK to offer protection against cell death 
(Gottlob et al., 2001; Mergenthaler et al., 2013). Furthermore, Majewski et al. (2004) 
demonstrate that the protection offered through hexokinase-mitochondria interaction does not 
necessitate the presence of Bax and Bak. Thus, it seems that Bax and Bad do not play a 
significant role in mtHKII protection against IR injury.   
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 Targeting Hexokinase to Mitochondria (Figure 3) 
 
It is clearly established in numerous cardiovascular disease models and in skeletal muscle 
ischemia-reperfusion interventions that the amount of HKII bound to mitochondria is a major 
determinant of infarct size and/or disease progression (Smeele et al., 2010, 2011A, 2012; Wu 
et al., 2011, 2012). In fact, the Halestrap laboratory recently reported a strong inverse 
correlation between the amount of end-ischemic mtHKII and infarct size in the isolated rat 
heart subjected to different perfusion condition: tripling of mtHKII reduced infarct size from 
65% to 5% (see Fig. 9, Pasdois et al, 2013).  Development of new therapies directed at 
increasing and/or keeping HKII at the mitochondria therefore seems like an attractive 
cardioprotective approach. Below we summarize the most promising interventions which 
have been shown to raise total HK or specifically mtHKII, for exploration of their (clinical) 
potential as adjunct therapy in settings of ischemia-reperfusion and possible chronic diseases 
such as diabetes, cardiac hypertrophy and heart failure.   
“Conditioning” of the heart: In 2005 we demonstrated that an IPC stimulus immediately 
translocates HK to the mitochondria in isolated rat hearts (Zuurbier et al., 2005). 
Subsequently, we have also shown that IPC also prevents HKII detachment from 
mitochondria during the irreversible period of ischemia (Gürel et al., 2009). These studies 
were later partly confirmed by Pasdois et al. (2011, 2013). Such IPC interventions can be 
performed clinically for leg or arm surgeries, but applicability for the heart is not directly 
feasible. However, the discovery that the heart can also be protected through remote ischemic 
preconditioning (RIPC) or post-conditioning, opened an avenue to cardiac application of the 
“conditioning” phenomenon.  Since the intracellular signalling pathways providing protection 
with IPC overlap to a large extent with those of RIPC (e.g. Li et al., 2011), it is anticipated 
that RIPC may also translocate HKII to mitochondria. This information is however lacking in 
the literature. Our currently active clinical mtHK-RIPC trial (NTR2915, Nederlands Trial 
Register) of RIPC in CABG patients, examines the relationship between RIPC protection and 
mtHKII in human atrial tissue, and will hopefully provide this much needed information.  
Insulin/PI3/Akt/GSK-3β –axis: Several studies have demonstrated that activation of this 
pathway will acutely (< 30 min)  increase HKII trafficking to the mitochondria (Russell et al., 
1992; Pastorino et al., 2005; Zuurbier et al., 2005, Southworth et al., 2007; Miyamoto et al., 
2008) and later on increases HKII expression.   Juhaszova et al. (2004) demonstrated that 
many cardioprotective agents confer protection through phosphorylation of GSK-3β and 
consequently inhibition of mPTP. Although many other studies can subsequently be found 
that have demonstrated cardioprotection with activation of this pathway, none of them have 
directly examined whether this was due to  increased mtHKII (e.g. Ng et al., 2012; Terashima 
et al., 2010; Hausenloy et al., 2005). A disadvantage of using this pathway to advance 
mtHKII is of course its pleiotropic character, with unwanted side effects increasing with every 
step upstream above HKII. For example, insulin may increase HKII translocation to 
mitochondria, but at the same time may not only result in hypoglycemia, but also in 
hypolipidemia (Zuurbier et al., 2008). It therefore seems advisable to use more specific 
treatment for increasing mtHKII. 
Anesthesia:  The use of specific anaesthetics for providing protection against IR injury is an 
attractive scenario in surgeries that necessitate anaesthesia. Pre-clinical studies in healthy, 
young animals almost all report protective effects of certain volatile anaesthetics (sevoflurane, 
isoflurane) and opiates (morphine). These protective anaesthetics also commonly activate the 
PI3/Akt/GSK-3β axis. However, these protective effects were not always observed in clinical 
studies employing e.g. CABG procedures (De Hert et al., 2011). The ambiguity in the clinical A
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scenario potentially results from co-morbidities (diabetes, aging, and hypertrophy) and co-
medications (e.g. statins, dexemethasones, opioids, nitroglycerine, β-blockers) which disturb 
the signalling pathway. Using several different anaesthetic regimens in healthy rats, we were 
able to demonstrate that the cardioprotective volatile anaesthetics sevoflurane and isoflurane 
did indeed maintain HK at cardiac mitochondria at a level similar to the non-anesthetised 
animal (Zuurbier et al., 2008). An anaesthetic regimen of propofol-sufentanil-morphine, also 
often used in the clinical arena, resulted in solubilisation of HK from the mitochondria. It can 
be speculated that the divergent effects of these two clinically most used anaesthetic regimens 
(volatile anaesthesia versus fentanyl-propofol anaesthesia) on mtHKII may also explain the 
dissipating effect of propofol anaesthesia on RIPC protection (Kottenberg et al., 2012). 
Further studies will be needed to test this hypothesis directly. In conclusion, although certain 
anesthetics may indeed offer protection through increases in mtHKII, the many cellular 
signalling steps that exist between the start of protection induced by an anaesthetic agent to 
the final subcellular HKII translocation is prone to be disturbed by many clinical and disease 
factors, thereby decreasing its likeliness as an ideal option offering IR protection under 
clinical conditions.  
Metformin: The glucose-lowering anti-diabetic drug metformin has been shown to be 
cardioprotective beyond its antihyperglycemic properties. It reduces infarct size in both 
diabetic and non-diabetic animals (Whittington et al., 2013;Bhamra et al., 2008;Calvert et al., 
2008;Solskov et al., 2008). In addition, multiple clinical studies showed reduced 
cardiovascular mortality in diabetic patients treated with metformin (El Messaoudi et al., 
2013). These cardioprotective effects may be caused by increased mtHK activity. Metformin 
treatment reverses the downregulation in total HK activity, and has been shown to increase 
HK translocation to the mitochondria in diabetic hearts without adversely affecting normal 
hearts (Da Silva et al., 2012). Whether metformin will increases (mt)HK in hearts during IR 
to afford protection remains to be examined, but 2 weeks of metformin treatment has 
previously been demonstrated to increase HK activity in rat white gastronemicus muscle 
(Suwa et al., 2006). This increase in HK might be explained by an increase in Akt 
phosphorylation after metformin treatment during reperfusion (Bhamra et al., 2008). 
However, Akt phosphorylation was not observed when metformin was given before 
ischaemia (Bhamra et al., 2008; Calvert et al., 2008). Alternatively, metformin may increase 
HK activity through activation of AMPK. Increases in AMPK activity have been associated 
with increased HK activity in skeletal muscle (Holmes et al., 1999; Dieni & Storey, 2011). 
Metformin may activate AMPK through increases in AMP resulting from inhibition of 
complex I (Owen et al., 2000) and/or AMP deaminase (Ouyang et al., 2011; Vytla et al., 
2013). Metformin is one of the most long-standing prescribed drugs in diabetes, showing 
relatively high efficacy. It will be interesting to elucidate whether a common mechanism of 
this drug entails the translocation of HK to the mitochondria, to identify a cellular 
mechanisms for its cardioprotective effects.    
miR-155/miR-143 therapy: MicroRNAs (miR) have recently been discovered as yet another 
level of regulation in biological function.  miRs are non-protein-coding RNAs of 20-30 
nucleotides, which silence gene expression at the post-transcriptional level by targeting the 3’-
untranslated region of messenger RNA. The use of miR therapeutics in cardiovascular 
medicine is only starting to develop, although several studies have already demonstrated the 
feasibility of such an approach (Thum, 2011). HKII has been shown to be regulated by miR-
155 and miR-143 in cancer cells(Jiang et al., 2012; Peschiaroli et al., 2012). Increases in miR-
155 induced HKII expression through activation of a HKII transcriptional activator (STAT3) 
and repression of a negative regulator of HKII, miR-143. Matkovich et al. (2013) recently 
demonstrated that cardiac overexpression of miR-143 was also able to suppress HKII mRNA 
in the heart with no indirect target regulation. Therapies may therefore be developed which A
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employ synthetic complementary oligonucleotides against miR-143 and/or adeno-associated 
virus containing miR-155 to specifically increase cardiac HKII and offer protection during IR 
interventions. 
Heat shock proteins: HKII has recently shown to be released from mitochondria in tumour 
cells during inhibition of mitochondrial HSP90 (Chae et al., 2012). HSP90 has previously 
been demonstrated to have cardioprotective capacity (Latchman et al, 2001; Xiang et al., 
2010)  and the mitochondrial heat shock protein, tumour necrosis factor receptor-associated 
protein 1 (TRAP1), is known to be present in the heart (Xiang et al., 2010). A therapy 
directed at increasing mitochondrial HSPs, either through heat treatment or gene therapy, may 
therefore also have cardioprotective potential by increasing mtHKII.      
 
 
Detrimental effects of persistent elevated mtHKII in the heart? 
 
The previous sections illustrate the many pro-survival effects of augmenting HKII-
mitochondria binding within the heart. This raises the question that if mtHKII is such a 
powerful protector of the myocardium, why is HKII not permanently bound to mitochondria 
in the healthy heart? We hypothesize that irreversibly bound mtHK would hamper the natural 
occurrence of mitochondrial depolarisation needed to maintain mitochondria healthy. Since 
mitochondrial depolarisation is a trigger signal for mitochondrial recycling through 
mitophagy, prevention of depolarisation may result in accumulation of dysfunctional 
mitochondria and ultimately a dysfunctional heart. This is supported by the apparent benefit 
afforded by dichloroacetate (DCA) in the treatment of pulmonary hypertension, right heart 
failure (McMurtry et al., 2004), hyperthyroid hypertrophy
 
(Atherton et al., 2011) and cancer 
(Bonnet et al., 2007; Michelakis et al., 2010). DCA induces mitochondrial depolarisation, 
which may at least partly be explained through disruption of hexokinase-mitochondrial 
binding (Michelakis et al., 2010).  The often observed hyperpolarised mitochondria in cancer 
cells (Bonnet et al., 2007; Chen et al., 1988) is consistent with their increased mtHKII as 
characterised by the Warburg effect. Permanently increasing mtHKII binding would also 
increase baseline aerobic glycolysis, and subsequently retard cellular signalling and 
mitochondrial activation, required for rapid responsive change in cardiac workload (Zuurbier 
et al., 2002; Harrison et al., 2003). Such retardation of mitochondrial activation may 
temporarily impair the free energy of ATP hydrolysis through elevation of cytosolic ADP 
(Van Beek et al., 1998). Finally, the upregulated glycolysis caused by permanent association 
of HK to cardiac mitochondria would presumably switch off fatty acid oxidation through the 
Randle effect, resulting in a less efficient heart when oxygen is not limiting, and a redirection 
of fatty acids towards lipid accumulation in the heart. The chronic elevated glucose uptake 
may also result in an increased accumulation of glucose-6-phosphate, resulting in chronic 
mTOR activation concomitant with an activated ER stress response (Sen et al., 2013). 
Interestingly, lipid accumulation, chronic mTOR activation and ER stress are all biochemical 
markers of cardiac failure (Sharma et al., 2004; Shioi et al., 2003), a known condition with 
elevated cardiac HK. It should be realised that the schemes discussed above are purely 
hypothetical, no evidence currently exists that has demonstrated detrimental effects of 
excessive mtHKII levels for the heart. However, future work may be devised to provide 
answers to these important questions of possible detrimental effects of too much mtHKII for 
the heart. 
 
In conclusion, the association of HKII with mitochondria is a critical determinant of 
cardiomyocyte death, making it a potential drug target in the treatment of cardiovascular 
ischemic diseases. It seems that in HK-mitochondrial binding, the two human diseases with A
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the largest impact on human mortality and morbidity, cancer and cardiovascular disease, share 
a similar, but directionally opposing, cellular mechanism: mtHK binding is increased in 
malignant cancer providing it with resilience against cell death, whereas it is decreased during 
cardiac infarction and thereby contributes to cardiac cell death. The challenge is now to target 
this mechanism which governs whether cells live or die in the treatment of cardiovascular 
diseases, with a minimum of collateral damage.  
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Figure Legends 
 
 
 
Figure 1 Schematic representation of cardiac disease states with low or high sensitivity to 
IR injury which is associated with protected mitochondria (high mtHK) or 
vulnerable mitochondria (low mtHK), respectively. 
 
Figure 2 Schematic drawing of the mitochondrial permeability transition pore complex 
dictating cell death through decreases in mtHK induced by ischemia-reperfusion. 
The most likely mechanisms (1-4) through which disruption of hexokinase II – 
mitochondrial binding may cause cell death are displayed. (see text for further 
discussion). 
 
Figure 3 Intracellular signalling pathways showing how different interventions 
(“conditioning”) and compounds such as cytokines, insulin, metformin, miRNA’s 
and anesthetics may increase HKII expression and/or HKII translocation to 
mitochondria. GPCR, G protein-coupled receptor; IR, insulin receptor ;JAK, Janus 
kinase; SOCS1, suppressor of cytokine signalling 1; STAT3, signal transducer and 
activator of transcription3; AMPK, AMP-activated protein kinase; PI3K, 
phosphoinositide 3-kinase; Akt, protein kinase B; PKC, protein kinase C; GSK, 
glycogen synthase kinase;C1, complex I of the electron transport chain.  
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